|
 |
luteinizing hormone-releasing hormoneThis page contains recent news articles, when available, and an overview of luteinizing hormone-releasing hormone but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.To evaluate the efficacy of zoledronic acid (ZA) in osteoporotic patients with prostate cancer receiving either luteinizing hormone-releasing hormone ... UroToday AEterna Zentaris announces termination of agreement with Sanofi-Aventis US - Dec 22, 2009 Cetrorelix, a luteinizing hormone-releasing hormone antagonist, had been the object of the Phase III program in BPH, a non-cancerous enlargement of the ... Trading Markets (press release) Æterna Zentaris terminates agreement with sanofi-aventis US for development ... - Dec 23, 2009 Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, had been the object of a phase-3 programme in BPH, a non-cancerous enlargement of the ... pharmabiz.com Æterna Zentaris Announces Termination of Agreement with sanofi-aventis US ... - Dec 18, 2009 Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, had been the object of a Phase 3 program in BPH, a non-cancerous enlargement of the ... CNNMoney.com (press release) Firmagon(R) has a Significantly Greater Probability of PSA Recurrence-Free ... - Dec 21, 2009 ...a gonadotropin-releasing hormone (GnRH) antagonist, with the luteinizing hormone-releasing hormone (LHRH) agonist, leuprolide, in prostate cancer ... PR Newswire UK (press release) Watson Announces New Program to Help Promote Good Bone Health in Advanced ... - Dec 14, 2009 Androgen deprivation therapy – the use of synthetic luteinizing hormone releasing hormone analogs (LHRH) therapy – is an effective and commonly used ... CNNMoney.com (press release) Firmagon® erhöht verglichen mit Leuprorelin die Wahrscheinlichkeit eines PSA ... - Dec 22, 2009 ...einem Antagonisten des LHRH (Luteinizing Hormone-Releasing Hormone), verglichen wurde, zeigten, dass Degarelix den Testosteronspiegel im Zeitverlauf ... PresseEcho.de (Pressemitteilung) Ipsen's Decapeptyl® 6-Month Formulation Receives Marketing Authorization in ... - Nov 12, 2009 Triptorelin embonate 22.5 mg is a new 6-month-formulation of a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or ... WELT ONLINE AEterna Zentaris To Raise US$5.5 Million From Institutional Investors At US ... - Oct 19, 2009 Its lead product candidates include cetrorelix, a luteinizing hormone-releasing hormone antagonist that has completed Phase III trial for benign prostatic ... RTT News AEterna reports positive preliminary data from Phase II ovarian cancer trial - Nov 4, 2009 In a personalized healthcare approach, the study selected patients with tumors expressing luteinizing hormone-releasing hormone (LHRH) receptors, ... Trading Markets (press release) AEterna Zentaris Reports Positive Results For Phase 2 Prelim. Study Of Ovarian ... - Nov 2, 2009 In the study, 43 patients with tumors expressing luteinizing hormone-releasing hormone or LHRH receptors were selected. A preliminary evaluation showed that ... RTT News Bourse en ligne, actualité des cours et bourse en ligne - Nov 12, 2009 La triptoréline embonate 22,5 mg est la nouvelle formulation 6 mois de Debiopharm de l'agoniste de la LHRH (luteinizing hormone releasing hormone) pour le ... TF1 Misteri Menstruasi - Oct 22, 2009 LH-RH (luteinizing hormone releasing hormone) yang dikeluarkan hipotalamus untuk merangsang hipofisis mengeluarkan LH. 3. ... Kabar Indonesia … and Sex Steroid Response to Luteinizing Hormone-Releasing Hormone ... - Oct 1, 2006 Luteinizing hormone-releasing hormone (100 µg IV) produced a response of LH, FSH, testosterone, and estradiol in children with premature pubarche that was ... Journal of Clinical Endocrinology and... … of Luteinizing Hormone-Releasing Hormone Analog-Induced Pubertal … - Mar 1, 2008 Fernando Cassorla, Verónica Mericq, Martha Eggers, Alejandra Avila, Cristian García, Ariel Fuentes, Susan R. Rose and Gordon B. Cutler, Jr. ... Journal of Clinical Endocrinology and... … Effect of D-Trp6-Luteinizing Hormone-Releasing Hormone in the... - Mar 1, 2005 Address all correspondence and requests for reprints to: Ricardo H. Asch, MD, Department of Obstetrics and Gynecology, The University of Texas Health ... Journal of Clinical Endocrinology and... … After Cessation Of Long-Term Luteinizing Hormone-Releasing Hormone... - Apr 19, 2008 UroToday.com - A longer duration of androgen deprivation therapy (ADT) results in a decreased likelihood of the recovery of testosterone. ... Medical News Today - Medical News Today (press release) Close Juxtapositions between Luteinizing Hormone-Releasing Hormone- … - Jan 1, 2005 Address all correspondence and requests for reprints to: Dr. Istvan Merchenthaler, Women's Health Research Institute, Wyeth Research, 500 Arcola Road, ... Journal of Clinical Endocrinology and... … Dosing Intervals For Luteinizing Hormone Releasing Hormone Agonists... - Jun 11, 2007 UroToday.com- Dr. Pathak and associates from Kaiser Permanente, Los Angeles published an article in the June 2007 issue of the Journal of Urology, ... Medical News Today - Medical News Today (press release) … and Magnitude of Episodic Luteinizing Hormone-Releasing Hormone … - Mar 1, 2008 Department of Medicine, Division of Endocrinology, The Milton S. Hershey Medical Center The Pennsylvania State University Hershey Pennsylvania 17033 ... Journal of Clinical Endocrinology and... … Excretion of Immunoreactive Luteinizing Hormone-Releasing Hormone-... - May 1, 2006 Department of Pediatrics, University of South Florida College of Medicine Tampa The Ed Wright Pediatric Endocrinology Research Laboratory,All Children's ... Journal of Clinical Endocrinology and... Luteinizing Hormone-Releasing Hormone Binds to Enriched Human … - Aug 1, 2007 Partially purified cell membranes were prepared from midterm and term placentas after sedimentation on a sucrose density gradient. ... Journal of Clinical Endocrinology and... … Pulsatile Administration of Luteinizing Hormone-Releasing Hormone... - Dec 1, 2008 Address requests for reprints to: Henriette A. Delemarre-van de Waal, Department of Pediatrics, Academic Hospital of the Vrije Universiteit, De Boelelaan ... Journal of Clinical Endocrinology and... Predictive value of luteinizing hormone releasing hormone (LHRH)... - Mar 1, 2005 Intravenous LHRH bolus testing (100 micrograms) after 36 h of pulsatile LHRH administration (5 micrograms/90 min) preliminary has been reported to allow ... Journal of Clinical Endocrinology and... … Pulsatile Administration of Luteinizing Hormone-Releasing Hormone... - Apr 1, 2006 Address requests for reprints to: Dr. J. Schoemaker, Division of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynecology, ... Journal of Clinical Endocrinology and... … Zentaris starts Ph II cancer trial.(luteinizing hormone-releasing... - Apr 18, 2005 Quebec City, Canada-based AEterna Zentaris has initiated a European multicenter, placebo-controlled Phase II clinical trial to evaluate the efficacy, ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Gonadorelin (Systemic). - Feb 1, 2006 Other commonly used names are luteinizing hormone -- releasing hormone (LHRH), luteinizing hormone -- releasing factor dihydrochloride (for gonadorelin ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Biallelic mutations in the prokineticin-2 gene in two sporadic cases... - Sep 29, 2007 Correspondence: Dr C Dodé, Département de génétique et développement, Institut Cochin, 24 rue du Faubourg Saint Jacques, 75014 Paris, France. ... Nature.com Are changes in US practices for androgen deprivation therapy financial... - Jun 16, 2008 Correspondence *Division of Urologic Surgery at Washington University School of Medicine, Box 8242, 660 S. Euclid Avenue, St Louis, MO 63110, USA ... Nature.com AEterna Zentaris Reports Positive Top Line Phase 1 Results for AN-152... - Nov 27, 2006 QUEBEC CITY, Nov. 27 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today disclosed additional positive top line Phase 1 results ... Free with registration - PR Newswire - AccessMyLibrary.com Can PSA nadir predict prognosis in men receiving hormonal therapy for... - Dec 30, 2005 Stewart AJ et al. (2005) Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. ... Nature.com AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R)... - Sep 22, 2008 WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an ... RedOrbit Gonadorelin (Systemic).(Drug overview) - Aug 1, 2006 Other commonly used names are luteinizing hormone -- releasing hormone (LHRH), luteinizing hormone -- releasing factor dihydrochloride (for gonadorelin ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com cancerfacts.com - About Breast Cancer - Jun 6, 2007 Systemic treatments are drugs and agents that are administered through the bloodstream and can affect all parts of the body. In breast cancer, the three ... Cancerfacts.com Learn about Bicalutamide from Consumer Reports Health. - Jan 3, 2008 Bicalutamide is used with another medication (luteinizing hormone-releasing hormone [LHRH]; such as leuprolide or goserelin) to treat metastatic prostate ... consumerreports.org Spectrum Pharmaceuticals Announces Phase 2 Data For Ozarelix In … - Aug 3, 2006 This trial is an open-label Phase 2 trial evaluating different intramuscular dosage regimens of the Luteinizing Hormone Releasing Hormone (LHRH) antagonist, ... Medical News Today - Medical News Today (press release) Management of clinically localized prostate cancer by radical … - Jan 25, 2005 Background A 65-year-old married man requested a PSA screening test and was found to have an elevated PSA level of 5.26 ng/ml. ... Nature.com Safety and clinical efficacy of a new 6-month depot formulation of … - Jul 14, 2008 Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for ... Nature.com Spectrum Pharmaceuticals Announces Phase 2 Data For Ozarelix In … - Aug 5, 2006 This trial is an open-label Phase 2 trial evaluating different intramuscular dosage regimens of the Luteinizing Hormone Releasing Hormone (LHRH) antagonist, ... Medical News Today - Medical News Today (press release) Aspirin Therapy Can Impair Prostate Cancer Treatment - Dec 27, 2007 By Crystal Phend, Staff Writer, MedPage Today. BOSTON, Dec. 27 -- Regular use of even low-dose aspirin may interfere with androgen suppression therapy for ... MedPage Today AEterna Zentaris Announces Completion of Patient Enrollment for … - Nov 21, 2005 Ozarelix is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone) antagonist administered as a depot formulation for the treatment of ... Free with registration - PR Newswire - AccessMyLibrary.com Two Pools of Luteinizing Hormone in the Human Pituitary: Evidence... - Jul 1, 2008 The pituitary gonadotrophin response to constant intravenous infusions of hypothalamic luteinizing hormone-releasing hormone (LH-RH), 0.2 µg/min for 4 hr, ... Journal of Clinical Endocrinology and... AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 Data... - May 23, 2007 QUEBEC CITY, May 23 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS), a global biopharmaceutical company focused on endocrine ... Free with registration - PR Newswire - AccessMyLibrary.com Paladin and Watson Enter Into Marketing and Supply Agreement for … - May 2, 2005 MONTREAL -- Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, today announced that it has entered into a Canadian marketing ... $4.95 - Business Wire - ECNext AEterna Zentaris Presents Detailed Positive Phase 2 Data on Ozarelix... - Nov 13, 2006 QUEBEC CITY, Nov. 13 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today presented detailed positive Phase 2 results in ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release - Data Shows Hormonal Therapy with Zolaxex® (goserelin … - Sep 3, 2007 It is the most widely researched Luteinizing Hormone-Releasing Hormone (LHRH) agonist7, having first been licensed in 1987, and has the broadest range of ... UroToday International Journal Gonadotropins; Hormone release and secretion studied, effects of … - Apr 30, 2005 2005 APR 30 - (NewsRx.com) -- Recently published research from Spain has reported on the effects of polypeptide YY3-36 (PYY3-36) upon luteinizing ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Thrombocytopenia Prevention; New thrombocytopenia prevention study … - Oct 30, 2006 2006 OCT 30 - (NewsRx.com) -- Fresh data on thrombocytopenia are presented in the report "Prevention of severe menorrhagia in oncology patients with ... Pay-Per-View - OBGYN & Reproduction Week - Factiva, from Dow Jones Jung Chan Investment Inc acquires Ta Ho Electronics Inc (pending) - … - Jun 30, 2008 TAIWAN - Jung Chan Investment Inc (JC), a wholly-owned unit of Jung Chan Investment Inc, agreed to acquire a ##% interest in Ta Ho Electronics Inc, ... Pay-Per-View - deals - Alacra Store Gonadotropins; Hormone release and secretion studied, effects of … - Apr 25, 2005 2005 APR 25 - (NewsRx.com) -- Recently published research from Spain has reported on the effects of polypeptide YY3-36 (PYY3-36) upon luteinizing ... Pay-Per-View - OBGYN & Reproduction Week - Factiva, from Dow Jones Press Release: Spectrum Pharmaceuticals Announces Phase 2 Data for … - Aug 2, 2006 Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone LHRH antagonist administered as a depot formulation that is being studied as a ... Pay-Per-View - PR Newswire - HighBeam Research Watson Pharmaceuticals' TRELSTAR(R) DEPOT and TRELSTAR(R) LA ( … - Apr 4, 2005 ...one- and three-month intramuscular injectable formulations of triptorelin pamoate, a luteinizing hormone releasing hormone (LHRH) agonist. ... RedOrbit Roles of the Urologist and Nurse from the Perspective of Patients... - Jun 20, 2008 To establish the roles of the urologist, general practitioner (GP) and nurse from the perspective of the patient with prostate cancer receiving hormone ... UroToday International Journal AEterna Zentaris Gains Market Approval for Cetrotide (cetrorelix) in... - Apr 20, 2006 Cetrorelix is part of our luteinizing hormone releasing hormone (LHRH) antagonist therapeutic approach. This peptide-based active substance was developed by ... DG News Vaccine Development; Synthetic vaccine promotes antibody or cytotoxic... - Jan 14, 2005 2005 JAN 14 - (NewsRx.com & NewsRx.net) -- A totally synthetic vaccine of generic structure targets Toll-like receptor 2 on dendritic cells and promotes ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Watson submits NDA for a 6-month formulation of Trelstar for the … - Nov 14, 2008 ...a luteinizing hormone releasing hormone (LHRH) agonist, has been accepted for filing by the US Food and Drug Administration (FDA). ... $9.94 - M2 Europharma - Alacra Store Press Release: Spectrum Authorized by FDA to Conduct Phase I/II … - May 31, 2005 SPI-153 is a Fourth Generation LHRH (Luteinizing Hormone Releasing Hormone) Antagonist Administered as a Depot Formulation ... Pay-Per-View - PR Newswire - HighBeam Research AEterna Zentaris Completes Patient Recruitment for Second Efficacy... - Oct 1, 2008 Cetrorelix is part of AEterna Zentaris' Luteinizing Hormone Releasing Hormone (LHRH) antagonist therapeutic approach. This peptide-based active substance ... Genetic Engineering News - Genetic Engineering News (press release) Failure to Achieve Castration Levels in Patients Using Leuprolide... - Jan 2, 2006 ...that some patients treated with luteinizing hormone releasing hormone analogues (LHRH analogues) fail to reach castration levels of serum testosterone. ... UroToday International Journal AEterna Enters Second Stage of Patient Recruitment for Phase II... - Oct 3, 2008 AEterna Zentaris, a biopharmaceutical company, has entered the second stage of patient recruitment for its Phase II trial in ovarian cancer with AEZS-108, ... RedOrbit Preferences of Healthy Men for Two Different Endocrine Treatment … - Oct 15, 2005 Objective:The aim of this study was to determine whether healthy men would prefer either luteinizing hormone releasing hormone analogues (LHRHa) or ... RedOrbit Press Release: AEterna Zentaris Enters a License and Collaboration … - Aug 3, 2006 ...a licensing and collaboration agreement with Nippon Kayaku for its fourth generation luteinizing hormone-releasing hormone (LHRH) antagonist, ozarelix. ... Pay-Per-View - PR Newswire - HighBeam Research Vaccine Development; Synthetic vaccine promotes antibody or cytotoxic... - Jan 11, 2005 2005 JAN 11 - (NewsRx.com & NewsRx.net) -- A totally synthetic vaccine of generic structure targets Toll-like receptor 2 on dendritic cells and promotes ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Press Release: Watson Announces the NDA for a 6-Month Formulation of ... - Nov 13, 2008 ...a luteinizing hormone releasing hormone (LHRH) agonist, has been accepted for filing by the U.S. Food and Drug Administration (FDA). ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Spectrum Pharmaceuticals Announces a License and … - Aug 3, 2006 Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone LHRH antagonist administered as a long-acting formulation that is being studied as a ... Pay-Per-View - PR Newswire - HighBeam Research AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights for … - Jan 30, 2006 Cetrorelix is part of our Luteinizing Hormone Releasing Hormone (LHRH) antagonist therapeutic approach. This peptide-based active substance was developed by ... $4.95 - PR Newswire - ECNext Press Release: AstraZeneca Receives Six Months Pediatric Exclusivity... - Sep 22, 2008 AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: AEterna Zentaris' Partner, Spectrum, Discloses... - May 23, 2007 AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Business Update; Aeterna Zentaris launches Cetrotide (cetrorelix) in ... - Oct 16, 2006 2006 OCT 16 - (NewsRx.com) -- Aeterna Zentaris, Inc., (AEZ; AEZS) announced that Cetrotide (cetrorelix) has been launched in Japan for in vitro ... Pay-Per-View - OBGYN & Reproduction Week - Factiva, from Dow Jones Press Release: AEterna Zentaris Launches Cetrotide(R) (cetrorelix) in... - Sep 21, 2006 ..."We look forward to generating additional revenue with Cetrotide(R) (cetrorelix), the first luteinizing hormone-releasing hormone (LHRH) antagonist to be ... Pay-Per-View - PR Newswire - HighBeam Research <P>This article has been removed and is no longer available.</P> | … - Jun 23, 2008 This article has been removed and is no longer available. ... find This article is unavailable articles. Pay-Per-View - Canadian Corporate News - HighBeam Research Press Release: AEterna Zentaris Reports Positive Top Line Phase 1 … - Nov 27, 2006 AEterna Zentaris Reports Positive Top Line Phase 1 Results for AN-152 in Patients with Gynaecological and Breast Cancers. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … and Releasing Actions of Luteinizing Hormone-Releasing Hormone * - Sep 1, 2006 Address all correspondence and requests for reprints to: Dr. Samuel SC Yen, Department of Reproductive Medicine, T002, University of California, San Diego, ... Journal of Clinical Endocrinology and... Phase II trial of tamoxifen and goserelin in recurrent epithelial... - May 31, 2005 Endocrine therapy is a recognised option in the treatment of chemo-resistant ovarian cancer. We conducted a nonrandomised phase II evaluation of combination ... Nature.com … rhesus monkeys preventable by luteinizing hormone-releasing... - Dec 1, 2008 Division of Reproductive Endocrinology and Infertility, MetroHealth Medical Center/Case Western Reserve University, Cleveland, Ohio 44109- 1998. ... Journal of Clinical Endocrinology and... Prostate cancer: New studies of combination therapy. - Jan 1, 2005 Doctors have finally begun to understand prostate cancer. Geneticists have identified abnormal genes that increase a man's vulnerability to the disease. ... Free with registration - Harvard Men's Health Watch - AccessMyLibrary.com Combined Treatment Approach Increases Survival In Prostate Cancer - Apr 8, 2005 Men with prostate cancer treated with the combined therapies had a significantly higher chance of living for more than 10 years than those on radiotherapy ... Medical News Today - Medical News Today (press release) Phase III Clinical Trial with 4-Month Long-Acting Formulation of... - Jun 11, 2007 Triptorelin is a metabolically stabilized analogue of LHRH (Luteinizing Hormone Releasing Hormone) an hypothalamic hormone secreted in a pulsatile fashion. ... Free with registration - Business Wire - AccessMyLibrary.com drug delivery system, ATRIGEL sustained release leuprorelin Sosei … - Mar 7, 2005 ...hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer. This subcutaneously-administered injection is designed ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Leuprolide acetate suppresses pedophilic urges and arousability.(clini... - Dec 1, 2005 Traditional treatment of pedophilia has focused on cognitive-behavioral psychotherapy alone and, more recently, cognitive-behavioral psychotherapy combined ... $4.95 - Archives of Sexual Behavior - ECNext Insulin resistance in polycystic ovarian disease.(CME Topic) - Sep 1, 2005 Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. ... Free with registration - Southern Medical Journal - AccessMyLibrary.com Euronext - Van genoteerde ondernemingen > Persberichten - Nov 6, 2007 About triptorelinTriptorelin is a metabolically stabilized analogue of LHRH (Luteinizing Hormone Releasing Hormone) an hypothalamic hormone secreted in a ... euronext.com Insulin resistance in polycystic ovarian disease.(CME Topic) - Sep 1, 2005 Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. ... $4.95 - Southern Medical Journal - ECNext Martha Rosenberg: Skinny Bitches and Vegansexuals add "spice" to meat... - Aug 17, 2007 ...by Martha Rosenberg. Salad is out and red meat is in on the first date says The New York Times in an August article. Fortifying yourself with food before a ... buzzflash.com FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) For … - Dec 31, 2008 ...the 1940s until the mid-1980s when the earliest forms of medical castration, luteinizing hormone releasing hormone (LHRH) agonists, were introduced. ... Medical News Today - Medical News Today (press release) Skinny "Bastards" and Pastors Join "Bitches" in Praising V-word - Aug 15, 2007 By Martha Rosenberg (about the author) Page 1 of 2 page(s). Salad is out and red meat is in on the first date says the New York Times in an August article. ... OpEdNews Spectrum Pharmaceuticals Launches, Phase 2 Multicenter, Clinical... - Apr 11, 2005 SPI-153 is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone, also known as GnRH (Gonadotropin Releasing Hormone) antagonist. ... RedOrbit Spectrum Authorized By FDA to Conduct Phase I/II Clinical Trial in... - May 31, 2005 SPI-153 is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone), also known as GnRH (Gonadotropin Releasing Hormone) antagonist. ... RedOrbit Ipsen: Clinical Update For Decapeptyl(R) 6-Month Formulation in … - Feb 12, 2008 ...its new 6-month formulation of Decapeptyl([R]1), a luteinizing hormone releasing hormone agonist (LHRHa) for the treatment of advanced prostate cancer. ... Free with registration - Business Wire - AccessMyLibrary.com Ipsen Announces The Filing Of Decapeptyl(R) 6-month Formulation For … - Sep 25, 2008 ...a luteinizing hormone releasing hormone agonist (LHRHa) developed by Debiopharm for the treatment of locally advanced or metastatic hormone-dependent ... Medical News Today - Medical News Today (press release) LH-RH agonists/GnRH agonists for prostate cancer - Jul 1, 2008 Luteinizing hormone-releasing hormone (LH-RH) agonists and gonadotropin-releasing hormone (GnRH) agonists are hormone therapy drugs that lower the ... MSN Health & Fitness Senior Health Report -- Health News for Seniors About Alzheimer's - May 15, 2006 Leuprolide acetate, when used in conjunction acetylcholinesterase inhibitors, appears to stabilize the cognitive and functional decline of women with ... Senior Health Report Prostate Cancer Updates - Apr 8, 2006 By Charlotte LoBuono. According to the Prostate Cancer Foundation (PCF), it is estimated that this year, 230000 new cases of prostate cancer will be ... UroToday International Journal Prostate with grief: aging baby boomers urgently need innovative … - Mar 7, 2005 According to the Prostate Cancer Foundation (PCF), it is estimated that this year, 230000 new cases of prostate cancer will be diagnosed in the United ... Free with registration - Drug Topics - AccessMyLibrary.com Early breast cancer: LHRH agonists show considerable promise - Oct 7, 2008 ...and whose tumour cells are stimulated by the hormone oestrogen, can benefit from taking Luteinizing hormone releasing hormone (LHRH) antagonists, ... eurekalert.org Testosterone Levels Rebound after Androgen Deprivation - Apr 18, 2006 By David Douglas. NEW YORK APR 18, 2006 (Reuters Health) - Serum testosterone levels achieve normal values within about 6 months of neoadjuvant androgen ... Cancerpage.com LHRH Agonists Show Promise in Early Breast Cancer - Nov 18, 2008 ...and whose tumour cells are stimulated by the hormone oestrogen, can benefit from taking Luteinizing hormone releasing hormone (LHRH) antagonists, ... TopCancerNews.com Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase... - Aug 29, 2005 Ozarelix is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone), also known as GnRH (Gonadotropin Releasing Hormone), antagonist. ... $4.95 - PR Newswire - ECNext Prostate Diet - More Gatherer, Less Hunter - Feb 18, 2006 It does this indirectly, through its effect on the hypothalamus, as less luteinizing hormone releasing hormone is produced by the hypothalamus. ... Buzzle Depot Delivery System Maintains Steady Drug Level in Prostate Cancer ... - Feb 15, 2006 This was once achieved by daily injections of luteinizing hormone releasing hormone agonists. Now longer-term systems are employed, and the researchers ... Cancerpage.com Spectrum Pharmaceuticals Launches Multi-Center, Phase 2 Clinical... - Apr 13, 2005 SPI-153 is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone), also known as GnRH (Gonadotropin Releasing Hormone) antagonist. ... RedOrbit Assisted Reproduction; Cetrorelix and leuprolide acetate comparably … - Mar 21, 2005 2005 MAR 21 - (NewsRx.com) -- Data from an open label, randomized, multicenter study indicate that cetrorelix, a luteinizing hormone-releasing hormone ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones D 63153 Spectrum, AEterna Zentaris phase change II, Europe (benign … - Apr 25, 2005 ...phase II trial of D 63153 (SPI 153), a luteinizing hormone releasing hormone (LHRH) antagonist, in patients with benign prostatic hypertrophy (BPH). ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Assisted Reproduction; Cetrorelix and leuprolide acetate comparably … - Mar 25, 2005 2005 MAR 25 - (NewsRx.com) -- Data from an open label, randomized, multicenter study indicate that cetrorelix, a luteinizing hormone-releasing hormone ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Endocrinology; Studies advance knowledge in endocrinology research - Feb 15, 2005 2005 FEB 15 - (NewsRx.com & NewsRx.net) -- Endocrinology research advances have been reported from the United States. Study 1: Neurokinin B (NKB) neurons ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Assisted Reproduction; Cetrorelix and leuprolide acetate comparably … - Mar 26, 2005 2005 MAR 26 - (NewsRx.com) -- Data from an open label, randomized, multicenter study indicate that cetrorelix, a luteinizing hormone-releasing hormone ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Press Release: FDA Approves Ferring Pharmaceuticals' Degarelix ( … - Dec 24, 2008 ...the 1940s until the mid-1980s when the earliest forms of medical castration, luteinizing hormone releasing hormone (LHRH) agonists, were introduced. ... Pay-Per-View - PR Newswire Europe - HighBeam Research Endocrinology; Studies advance knowledge in endocrinology research - Feb 14, 2005 2005 FEB 14 - (NewsRx.com & NewsRx.net) -- Endocrinology research advances have been reported from the United States. Study 1: Neurokinin B (NKB) neurons ... Pay-Per-View - Proteomics Weekly - Factiva, from Dow Jones Unilateral breast enlargement in a 6-year-old girl - Jan 31, 2006 A mother with a family history of breast cancer discovers a subareolar mass in her otherwise normal daughter. Emily's mother was worried. ... Cortlandt Forum Press Release: Commercial availability of QLT's Eligard(R) 6-month … - Feb 17, 2005 Commercial availability of QLT's Eligard(R) 6-month formulation brings new treatment option for advanced prostate cancer. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research FDA Approves Degarelix For Advanced Prostate Cancer Treatment - Dec 25, 2008 ...the 1940s until the mid-1980s when the earliest forms of medical castration, luteinizing hormone releasing hormone (LHRH) agonists, were introduced. ... emaxhealth.com Press Release: Spectrum Pharmaceuticals Launches, Phase 2 … - Apr 11, 2005 SPI-153 is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone, also known as GnRH (Gonadotropin Releasing Hormone) antagonist. ... Pay-Per-View - PR Newswire - HighBeam Research Spectrum Pharmaceuticals Initiates US Clinical Trial of Ozarelix (SPI... - Jul 25, 2005 Ozarelix is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone), also known as GnRH (Gonadotropin Releasing Hormone), antagonist. ... $4.95 - PR Newswire - ECNext |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |